We’re pleased to share that the Novavax COVID-19 Vaccine, trialled here in Dorset, has been found to be 89.3% effective in preventing Coronavirus.
The Novavax vaccine trial, supported by the National Institute for Health Research (NIHR) is the largest ever double blind, placebo-controlled trial in the UK. It recruited over 15,000 participants from 35 UK research sites in just over two months, with 591 participants from Dorset taking part, at the Royal Bournemouth Hospital.
Dr Patrick Moore, our Lead Researcher and Local NIHR Investigator, comments:
“It’s fantastic to see the results of the Phase 3 trial, which show that this is a highly effective and safe COVID-19 vaccine – importantly, it also shows that this vaccine is effective against the UK variant that has spread so quickly.
“Almost 600 Dorset residents took part in this trial, and I’d like to thank them all for their contribution to this important research.
“Our county is playing a key part in the global search for COVID-19 vaccines, with the people of Dorset coming together with the NHS to find a way out of this pandemic.”
The UK government has already secured 60 million doses of the Novavax vaccine. Provided it continues to meet required standards, manufacturing will take place in Billingham, Stockton-on-Tees.